Surgical Lasers Inc. (SLI) Announces New Covid-19 Support Programs

Surgical Lasers Inc. (SLI) Announces New Covid-19 Support Programs Practical Access to State of the Art Lasers and Fibers for Lithotripsy & BPH to Address the Backlog of Elective Procedures

May 2020

As health professionals in the medical device industry, we are all aware of the impact of Covid-19 on our personal and professional lives.  We know that acting responsibly and practicing social distancing and self- isolation where relevant are the two most important actions we must respect in an effort to minimize the impact and expedite the process of recovery for patients, hospital personnel, front line workers, and the economy.

While we at SLI maintain our commitment to these fiduciary responsibilities, we are also intimately aware of the need to continue to maintain the standard and availability of health care services to those in need.  The conditions we treat are in some cases elective, but with delays in treatment come increases in severity and the inevitable evolution to non-elective/essential surgeries to deal with issues like kidney failure, urinary retention, pain & discomfort, etc.  This will surely create a backlog of patients for ureteroscopy and BPH surgery and a significant financial burden on hospitals and surgical centers currently faced with increased requirements on already limited budgets and resources.

As a commitment to support the continued quality and availability of care for urology patients in need, Surgical Lasers Inc. is sponsoring unique programs that will give surgery centers and hospitals affordable, practical access to the equipment required to deliver these essential services.  These programs include all-inclusive “cost per case” financing and deferred payment alternatives.  The all-inclusive “cost per case” programs include the use of the laser, single-use disposable fiber, and optional training and certification of staff members.  Given there is no requirement outright purchase the laser system, there is no need to allocate funds from already limited budgets and the overall cost to the facility is significantly more affordable than capital acquisition or current rental alternatives. 

Having the product remain onsite also ensures availability as resources from third party rental companies become strained with excess demand. Another significant and unique characteristic that enhances the versatility of all the SLI laser systems is the fact that they all run on standard 110V power and can work in ANY room in the surgical center or hospital.

Furthering efforts to minimize the financial impact of dealing with the backlog, SLI is temporarily waiving all delivery, installation, set-up and training fees and provides the client with no-charge certification training for existing staff, or the option of having personnel available to operate the devices.  Given the lasers will remain onsite, there will also be no more concern relative to cancellation fees.

Our commitment to place our state of the art family of surgical lasers at a competitive cost and without the requirement to access capital budgets or resources from rental companies is the most practical and cost-effective solution for these services available on the market today!  It also represents an excellent opportunity for clinicians to experience the clinical and operational benefits of excellence in engineering, from the longest pulsed, highest energy holmium laser for fragmentation, dusting, and various soft tissue applications, to the highest energy portable diode laser for vaporization or enucleation.

We remain committed to maintaining the quality and availability of care in consideration of the economic impact of Covid-19.  Please contact us at T: (905) 853-9090, Email: info@surgicallasersinc.com, or your local representative to learn more or with any questions you may have.

Surgical Lasers Inc. Highlights Versatility of the new Pathfinder Portable Laser for Office Based BPH Procedures

Innovative laser supports contact and lateral (side) fire fibers for vaporization as well as end fire fibers for enucleation

September 8th, 2017 – Newmarket, ON

Surgical Lasers Inc. (SLI), a pioneer in innovative laser technologies with an emphasis on continuous improvement initiatives for legacy systems, announced today the availability of three (3) unique consumable fibers, for its new Pathfinder portable diode laser for BPH treatments. This announcement follows the successful launch of the Pathfinder earlier this year.

A clinically proven alternative for the treatment of enlarged prostates, various laser technologies are being used globally with a variety of optical fibers.  These include contact fibers and lateral (side) fire fibers for vaporization and end fire fibers for enucleation.  The new Pathfinder laser is the only portable laser currently available on the market which supports all three fiber types, hence can be used for either vaporization or enucleation at the discretion of the surgeon.  This enhanced functionality differentiates this unique multidisciplinary laser platform from competitive systems which are limited to working with a single fiber technology.

The ability to enucleate with this innovative device also provides a safe, effective and practical alternative to Holmium Laser Enucleation of the Prostate (HOLEP), performed with high energy holmium lasers, which are typically much larger, and require 220/240v power.  By comparison, the Pathfinder diode laser is a portable device (<30kg) which runs on standard 115V power. Over and above the practical advantages of implementing the portable diode laser for enucleation, its enhanced ability to coagulate may improve the efficiency of the procedures by improving visibility.

An integral component of any laser surgery with a fiber based system is the consumable or reusable optical fiber and the availability of all three fibers means urologists can realize the benefits of the new Pathfinder portable diode laser for either laser vaporization or enucleation of the prostate.  Clinical and operational advantages of this innovative device include efficient and effective vaporization with durable coagulation and, in consideration of the technique, and at the discretion of the surgeon, it is possible to perform procedures in the operating room, surgical center and private office under either local or general anesthetic.

Surgical Lasers Inc. Showcases Its New HYPHO Holmium Laser at the American Urological Association (AUA) Annual Meeting

An Evolution in Holmium Laser Engineering optimizing performance and control

May 12th, 2017 – Newmarket, ON

Surgical Lasers Inc. (SLI) further solidified its mission of introducing innovative, practical, clinically effective yet minimally invasive laser technology to the market, with the official launch of the new HYPHO holmium laser technology at the American Urological Association (AUA) 2017 Annual Meeting in Boston, MA.  Proprietary engineering differentiates this compact technological innovation which delivers control and performance specifications consistent with much larger, higher power devices requiring 220/240 VAC power.

The addition of the new HYPHO holmium laser to the SLI product family is consistent with a corporate commitment to continuous improvement initiatives with a focus on introducing the market to practical alternatives to existing legacy systems.  Technological breakthroughs from the HYPHO’s intelligent engineering optimize both performance and control.

The HYPHO is an affordable, compact (<53kg) holmium laser which runs on 115V power and redefines the performance capabilities of a compact holmium laser with the highest output energy (joules) of any holmium laser in its class.  Furthermore, the HYPHO delivers the longest pulse duration of any holmium laser on the market today, which maximizes control and minimizes retropulsion and inadvertent stone migration, of particular importance when working on calculi in the kidney and upper ureter.[1]

The unparalleled (industry’s longest) pulse duration of the new HYPHO laser is also indicated to facilitate the more controlled process of stone ablation referred to as ‘dusting’, with longer pulse durations producing a greater photo-thermal effect on the target tissue.[2]  Also referred to as ‘long fragmentation’, combinations of long pulse duration and variable frequencies facilitates the ability to ablate or ‘dust’ away smaller particles from the perimeter of calculi in the absence of mobility, a key differentiator of this technology vs. other compact < 35 watt holmium lasers.

Traditionally facilitated with higher powered (220/240V) holmium lasers requiring higher frequencies, the ability to deliver similar performance using this innovative compact, 115V, 35 watt laser provides the market with a credible, viable alternative for the most current laser lithotripsy techniques.

Finally, longer pulse durations provide further benefit in improving coagulation in holmium laser soft tissue surgery and maintaining the integrity of the fiber(s), further enhancing performance and protecting the investment in consumables.  The HYPHO holmium laser works with various SLI manufactured fiber sizes ranging from 200 – 1000µm.

In parallel with the US launch of the HYPHO, SLI looks forward to the feedback from scheduled upcoming product evaluations with leading international experts and opinion leaders experienced in the latest innovations in high-performance holmium laser systems for fragmentation as well as stone dusting.


[1] Impact of pulse duration on Ho:YAG laser lithotripsy: fragmentation and dusting performance

Markus J. Bader · Thomas Pongratz · Wael Khoder · Christian G. Stief · Thomas Herrmann · Udo Nagele · Ronald Sroka  Received: World J Urol (2015) 33:471–477 DOI 10.1007/s00345-014-1429-8 19 July 2014 / Accepted: 19 October 2014 / Published online: 4 November 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

[2] Chan KF, Vassar GJ, Pfefer TJ, Teichman JM, Glickman RD, Weintraub ST, et al. Holmium:YAG laser lithotripsy: a dominant photothermal ablative mechanism with chemical decomposition of urinary calculi. Lasers Surg Med (1999) 25(1):22–37. doi:10.1002/(SICI)1096-9101(1999)25:1<22::AID-LSM4>3.3. CO;2-Y